globenewswire health1 min read
saveOKYO Pharma CSO Raj Patil boosts stake to 20,030 shares
read at globenewswire health ↗DealNeutral
OKYO Pharma, a clinical stage biotech focused on neuropathic corneal pain and anterior segment eye diseases, disclosed that its chief scientific officer, Raj Patil, PhD, bought additional shares.
Patil purchased 3,363 ordinary shares on NASDAQ at $1.49 each, raising his total holding to 20,030 shares.
The transaction was announced via a Globe Newswire release on July 28, 2026, and reflects insider confidence in the company's development programs.
source
This writeup was produced by pharmadog from original reporting by globenewswire health.
Original headline: “OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer”
read at globenewswire health ↗170 words · retrieved Jul 29
comments(0)
5-min edit window · permanent after that